A Study of Three Drugs Plus Zidovudine in the Prevention of Infections in HIV-Infected Patients
Information source: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pneumonia, Pneumocystis Carinii; HIV Infections
Intervention: Pentamidine isethionate (Drug); Sulfamethoxazole-Trimethoprim (Drug); Dapsone (Drug); Zidovudine (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: National Institute of Allergy and Infectious Diseases (NIAID) Official(s) and/or principal investigator(s): S Bozzette, Study Chair S Spector, Study Chair
Summary
To evaluate and compare 3 anti-pneumocystis regimens plus zidovudine (AZT) in persons with
HIV infection and T4 cell count less than 200 cells/mm3. All persons completing at least 8
weeks of therapy on 081 will be offered the opportunity to participate in the nested study
(ACTG 981) of systemic antifungal therapy (fluconazole) versus local therapy (Clotrimazole)
for the prevention of serious fungal disease.
Persons with HIV disease who are receiving AZT are at risk for PCP, toxoplasmosis, bacterial
pneumonia, and other serious infections. It is therefore important to find drugs that can be
given along with AZT to control these infections. Aerosolized pentamidine (PEN) has been
shown to be useful in preventing PCP and is expected to lower the 2-year risk of PCP. Both
sulfamethoxazole/trimethoprim (SMX/TMP) and dapsone probably also provide effective
preventive treatment against PCP, and both may be useful in preventing toxoplasmosis and
extrapulmonary pneumocystosis.
Clinical Details
Official title: A Randomized Trial of Three Anti-Pneumocystis Agents Plus Zidovudine for the Primary Prevention of Serious Infections in Patients With Advanced HIV Infection
Study design: Masking: Open Label, Primary Purpose: Treatment
Detailed description:
Persons with HIV disease who are receiving AZT are at risk for PCP, toxoplasmosis, bacterial
pneumonia, and other serious infections. It is therefore important to find drugs that can be
given along with AZT to control these infections. Aerosolized pentamidine (PEN) has been
shown to be useful in preventing PCP and is expected to lower the 2-year risk of PCP. Both
sulfamethoxazole/trimethoprim (SMX/TMP) and dapsone probably also provide effective
preventive treatment against PCP, and both may be useful in preventing toxoplasmosis and
extrapulmonary pneumocystosis.
All patients receive AZT. In addition, they are placed in one of three groups to receive
either SMX/TMP, dapsone, or PEN. Stratification criteria are:
Received first AZT equal to or less than 6 weeks prior to study entry. Received first AZT
more than 6 weeks prior to study entry. Potential to participate in ACTG 981. ACTG center in
which the patient is enrolled.
Eligibility
Minimum age: 13 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria
Concurrent Medication:
Allowed:
- Antifolate medication required to treat an intercurrent infection.
- Treatment of intercurrent infections or malignancies.
- Fluconazole.
- Itraconazole.
- Standard or investigational therapy for pneumocystosis (PCP) or toxoplasmosis.
- Only the forms of primary prophylaxis for PCP or toxoplasmosis assigned to the
participant under the protocol. Patients who develop intolerance to all forms of
prophylaxis assigned in this protocol or who develop PCP or toxoplasmosis may receive
alternate or investigation forms of prophylaxis with or without zidovudine but must
continue to be followed under this protocol.
- Discouraged but allowed: AL-721.
- Chronic acyclovir.
- Ketoconazole.
- Amphotericin B.
- Corticosteroids at greater than physiologic replacement doses are strongly
discouraged.
- They should be used as briefly as possible and only for definite specific
indications.
Patient must conform to the following:
- Receiving or candidates for zidovudine therapy at least 500 mg/day under current
labeled indications with no history of pneumocystosis (PCP) or toxoplasmosis.
- Evidence of HIV infection documented by HIV antibody tests.
- T4 cell count less than 200 cells/mm3 at any time prior to study entry.
- Willing to sign informed consent.
- Willing to be followed by a participating ACTG center for duration of the study.
- Allowed: Concurrent enrollment in long-term follow-up studies in previously blinded
trials of AZT (ACTG 016 and 019).
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions are excluded:
- History of documented or presumed pneumocystosis (PCP) or toxoplasmosis.
- Active bacterial or mycobacterial infection.
- History of type I hypersensitivity, exfoliative rash, or rash with mucosal
involvement, severe bronchospasm, or other life-threatening reaction to any of the
study drugs or to other sulfas, sulfones, or pentamidine.
- History of intolerance causing dose interruption while receiving zidovudine at equal
to or less than 600 mg/day or causing dose reduction to less than 500 mg/day within 4
weeks prior to entry.
- Advanced Kaposi's sarcoma or other malignancy not specifically allowed that has been
rapidly progressive during the month prior to enrollment or which may be expected to
require chemotherapy within 90 days of study entry.
Concurrent Medication:
Excluded:
- Active primary treatment for an infection or malignancy.
- Other form of antifolate medication not specifically allowed.
- Other antiretroviral or biologic response modifier.
- Ganciclovir, if it causes intolerance to AZT equal to or more than 500 mg/day.
- Foscarnet.
Patients with the following are excluded:
- Symptoms and conditions defined in Exclusion Coexisting Conditions.
- Glucose 6-phosphate dehydrogenase deficiency (GPD).
- History of pneumocystosis (PCP) or toxoplasmosis.
- History of type I hypersensitivity, exfoliative rash, or rash with mucosal
involvement, severe bronchospasm, or other life-threatening reaction to any of the
study drugs or to other sulfas, sulfones, or pentamidine.
- History of intolerance causing dose interruption while receiving zidovudine at
equal to or less than 500 mg/day with 4 weeks pior to study entry.
Prior Medication:
Excluded within 4 weeks of study entry:
- Any other form of pneumocystosis (PCP) chemoprophylaxis.
- Active substance abuse, including alcohol.
Locations and Contacts
Mbeya Med. Research Program, Mbeya Referral Hosp. CRS, Mbeya, Tanzania
USC CRS, Los Angeles, California 90033, United States
Children's Hosp. & Research Ctr. Oakland, Ped. Clinical Research Ctr. & Research Lab., Oakland, California 94609, United States
Ucsd, Avrc Crs, San Diego, California 92103, United States
Univ. of Miami AIDS CRS, Miami, Florida 33136, United States
Chicago Children's CRS, Chicago, Illinois 60614, United States
Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis, Indiana 46202, United States
Johns Hopkins Adult AIDS CRS, Baltimore, Maryland 21287, United States
Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts 02215, United States
Beth Israel Deaconess Med. Ctr., ACTG CRS, Boston, Massachusetts 02215, United States
Massachusetts General Hospital ACTG CRS, Boston, Massachusetts 02114, United States
University of Minnesota, ACTU, Minneapolis, Minnesota 55455, United States
Washington U CRS, St. Louis, Missouri, United States
SUNY - Buffalo, Erie County Medical Ctr., Buffalo, New York 14215, United States
Univ. of Rochester ACTG CRS, Rochester, New York, United States
Unc Aids Crs, Chapel Hill, North Carolina, United States
Duke Univ. Med. Ctr. Adult CRS, Durham, North Carolina, United States
Case CRS, Cleveland, Ohio 44106, United States
The Ohio State Univ. AIDS CRS, Columbus, Ohio 43210, United States
Pitt CRS, Pittsburgh, Pennsylvania, United States
University of Washington AIDS CRS, Seattle, Washington 98105, United States
Additional Information
Click here for more information about Zidovudine Click here for more information about Pentamidine isethionate Click here for more information about Sulfamethoxazole-Trimethoprim
Related publications: Bozzette SA, Hays RD, Berry SH, Kanouse DE. A Perceived Health Index for use in persons with advanced HIV disease: derivation, reliability, and validity. Med Care. 1994 Jul;32(7):716-31. Bozzette SA, Finkelstein DM, Spector SA, Frame P, Powderly WG, He W, Phillips L, Craven D, van der Horst C, Feinberg J. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med. 1995 Mar 16;332(11):693-9. Glick ME. CTG studies yield results. AIDS Clinical Trials Group. NIAID AIDS Agenda. 1995 Spring:8-9. Justice AC, Rabeneck L, Hays RD, Wu AW, Bozzette SA. Sensitivity, specificity, reliability, and clinical validity of provider-reported symptoms: a comparison with self-reported symptoms. Outcomes Committee of the AIDS Clinical Trials Group. J Acquir Immune Defic Syndr. 1999 Jun 1;21(2):126-33. Justice AC, Holmes W, Gifford AL, Rabeneck L, Zackin R, Sinclair G, Weissman S, Neidig J, Marcus C, Chesney M, Cohn SE, Wu AW; Adult AIDS Clinical Trials Unit Outcomes Committee. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol. 2001 Dec;54 Suppl 1:S77-90. Ioannidis JP, Dixon DO, McIntosh M, Albert JM, Bozzette SA, Schnittman SM. Relationship between event rates and treatment effects in clinical site differences within multicenter trials: an example from primary Pneumocystis carinii prophylaxis. Control Clin Trials. 1999 Jun;20(3):253-66. DiRienzo AG, van Der Horst C, Finkelstein DM, Frame P, Bozzette SA, Tashima KT. Efficacy of trimethoprim-sulfamethoxazole for the prevention of bacterial infections in a randomized prophylaxis trial of patients with advanced HIV infection. AIDS Res Hum Retroviruses. 2002 Jan 20;18(2):89-94.
Last updated: March 28, 2012
|